Articles by GU Oncology Now Editors
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Dr. Tawagi delved into the latest developments in bladder cancer treatment, beginning with the presentation of EV-302.
Articles from the December 2022 issue of the GU Oncology Now Journal
Articles from the November 2022 issue of the GU Oncology Now Journal
Articles from the October 2022 issue of the GU Oncology Now Journal
Cell-based therapies have shown efficacy in disease settings, but for solid tumors, research has proceeded at a slower pace.
Articles from the September 2022 issue of the GU Oncology Now Journal
Evan Ya-Wen Yu, MD, talks about different types of precision medicine, the future of precision medicine, and more.
Part two of an interview with Russell Szmulewitz, MD on the benefits of PSMA-PET for high-risk and advanced prostate cancer.
Part one of an interview with Russell Szmulewitz, MD on the benefits of PSMA-PET for high-risk and advanced prostate cancer.
Evan Ya-Wen Yu, MD, discusses what precision medicine is, how patients were treated before precision medicine, and more.
Prostate cancer highlights from ASCO 2022 are discussed, including the ENZAMET trial design and TheraP trial data.
Drs. Michael Morris and Akhil Saji discuss the future of PSMA-targeted therapies in advanced prostate cancer.
In this paper, we present age-standardized cancer incidence and mortality rates in the Faroe Islands.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.